NeuroLINCS Proteomics: Defining human-derived iPSC proteomes and protein signatures of pluripotency.
Andrea D MatlockVineet VaibhavRonald HolewinskiVidya VenkatramanVictoria DardovDanica-Mae ManaloBrandon ShelleyLoren OrnelasMaria BanuelosBerhan MandefroRenan Escalante-ChongJonathan LiSteven FinkbeinerErnest FraenkelJeffrey D RothsteinLeslie M ThompsonDhruv SareenClive N Svendsennull nullJennifer E Van EykPublished in: Scientific data (2023)
The National Institute of Health (NIH) Library of integrated network-based cellular signatures (LINCS) program is premised on the generation of a publicly available data resource of cell-based biochemical responses or "signatures" to genetic or environmental perturbations. NeuroLINCS uses human inducible pluripotent stem cells (hiPSCs), derived from patients and healthy controls, and differentiated into motor neuron cell cultures. This multi-laboratory effort strives to establish i) robust multi-omic workflows for hiPSC and differentiated neuronal cultures, ii) public annotated data sets and iii) relevant and targetable biological pathways of spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). Here, we focus on the proteomics and the quality of the developed workflow of hiPSC lines from 6 individuals, though epigenomics and transcriptomics data are also publicly available. Known and commonly used markers representing 73 proteins were reproducibly quantified with consistent expression levels across all hiPSC lines. Data quality assessments, data levels and metadata of all 6 genetically diverse human iPSCs analysed by DIA-MS are parsable and available as a high-quality resource to the public.
Keyphrases
- pluripotent stem cells
- electronic health record
- endothelial cells
- induced pluripotent stem cells
- amyotrophic lateral sclerosis
- healthcare
- big data
- mass spectrometry
- single cell
- mental health
- quality improvement
- stem cells
- public health
- newly diagnosed
- ejection fraction
- small molecule
- data analysis
- dna methylation
- gene expression
- risk assessment
- bone marrow
- adverse drug
- binding protein
- brain injury
- human health
- prognostic factors
- health promotion